Lactose Intolerance Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major lactose intolerance markets reached a value of US$ 10.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 20.9 Billion by 2034, exhibiting a growth rate (CAGR) of 6.23% during 2024-2034.
The lactose intolerance market has been comprehensively analyzed in IMARC's new report titled "Lactose Intolerance Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lactose intolerance refers to a digestive disorder caused by an inability to digest lactose, a major carbohydrate found in dairy products. This ailment is characterized by a deficiency in the enzyme lactase, which is required in the body to digest lactose. Depending on the causative factor, there are four types of lactose intolerance: primary, secondary, congenital, and developmental. The most common symptoms of the ailment include bloating, gas, diarrhea, abdominal cramps, nausea, etc. Typically, these indications appear one and a half to two hours after consuming milk-based foods or drinks. Individuals suffering from this condition may also experience an urgent need to go to the toilet, lower belly pain, vomiting, and constipation. The diagnosis of this condition involves a review of the patient's medical history, symptoms, and physical examination. The other supporting tests to confirm a diagnosis include a stool acidity test and a hydrogen breath test. Additionally, the healthcare provider may perform a lactose tolerance test to detect the absorbance of lactose in the digestive system by measuring blood glucose levels.
The increasing prevalence of genetic disorders on account of inherited gene mutations and structural defects is primarily driving the lactose intolerance market. Apart from this, the rising incidences of intestinal ailments, such as celiac disease, carcinoid syndrome, Crohn's disease, etc., which damage the cells that generate lactase, are also bolstering the market growth. Furthermore, the escalating usage of prescription medications, including rifaximin, to treat bacterial overgrowth in the small intestine that can exacerbate lactose intolerance indications, is creating a positive outlook for the market. Besides this, the widespread adoption of gut microbiome analysis for identifying specific bacteria that may be causing symptoms and guiding personalized treatment options, is acting as another significant growth-inducing factor. Moreover, numerous key players are making extensive investments in research activities to develop safer and cost-effective targeted therapies with a better understanding of disease pathology. This, in turn, is also propelling the market growth. Additionally, the growing demand for lactase enzyme supplements owing to their several associated benefits, including reduced symptoms, improved nutrient absorption, being well-tolerated with fewer side effects, easy availability, etc., is expected to drive the lactose intolerance market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the lactose intolerance market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for lactose intolerance and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lactose intolerance market in any manner.
Recent Developments:
In February 2024, Novartis announced that Xolair (omalizumab) has been approved by the US FDA to reduce allergic reactions, including anaphylaxis, that can occur after accidental ingestion of one or more foods in pediatric and adult and patients aged 1 year and above with IgE-mediated food allergy. The approval is based on findings from the NIH-sponsored Phase III OUtMATCH research, which demonstrated a considerably higher proportion of food allergy patients as young as one year treated with Xolair could tolerate tiny amounts of peanut, milk, egg, and cashew without an allergic reaction, compared to placebo.
Key Highlights:
About 65 percent of the human population has a diminished capability to digest lactose after infancy.
Lactose intolerance is most common in persons of East Asian heritage, with 70 to 100 percent of those affected in these cultures.
80 percent of all Native Americans and African-Americans are lactose intolerant.
Lactose intolerance appears to be more prevalent in patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D) than in healthy persons.
Lactose intolerance typically manifests in adults between the ages of 20 and 40.
Drugs:
Tilactase is a beta-D-galactosidase isolated from Aspergillus oryzae. The medication is used to treat the symptoms of lactose intolerance in babies and older patients who require parenteral nourishment or a fluid diet. It is produced as a chewable tablet that must be taken before consuming a lactose-containing meal.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the lactose intolerance market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the lactose intolerance market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current lactose intolerance marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the lactose intolerance market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the lactose intolerance market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the lactose intolerance market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of lactose intolerance across the seven major markets?
What is the number of prevalent cases (2018-2034) of lactose intolerance by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of lactose intolerance by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of lactose intolerance by type across the seven major markets?
How many patients are diagnosed (2018-2034) with lactose intolerance across the seven major markets?
What is the size of the lactose intolerance patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of lactose intolerance?
What will be the growth rate of patients across the seven major markets?
Lactose Intolerance: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for lactose intolerance drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lactose intolerance market?
What are the key regulatory events related to the lactose intolerance market?
What is the structure of clinical trial landscape by status related to the lactose intolerance market?
What is the structure of clinical trial landscape by phase related to the lactose intolerance market?
What is the structure of clinical trial landscape by route of administration related to the lactose intolerance market?
The lactose intolerance market has been comprehensively analyzed in IMARC's new report titled "Lactose Intolerance Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lactose intolerance refers to a digestive disorder caused by an inability to digest lactose, a major carbohydrate found in dairy products. This ailment is characterized by a deficiency in the enzyme lactase, which is required in the body to digest lactose. Depending on the causative factor, there are four types of lactose intolerance: primary, secondary, congenital, and developmental. The most common symptoms of the ailment include bloating, gas, diarrhea, abdominal cramps, nausea, etc. Typically, these indications appear one and a half to two hours after consuming milk-based foods or drinks. Individuals suffering from this condition may also experience an urgent need to go to the toilet, lower belly pain, vomiting, and constipation. The diagnosis of this condition involves a review of the patient's medical history, symptoms, and physical examination. The other supporting tests to confirm a diagnosis include a stool acidity test and a hydrogen breath test. Additionally, the healthcare provider may perform a lactose tolerance test to detect the absorbance of lactose in the digestive system by measuring blood glucose levels.
The increasing prevalence of genetic disorders on account of inherited gene mutations and structural defects is primarily driving the lactose intolerance market. Apart from this, the rising incidences of intestinal ailments, such as celiac disease, carcinoid syndrome, Crohn's disease, etc., which damage the cells that generate lactase, are also bolstering the market growth. Furthermore, the escalating usage of prescription medications, including rifaximin, to treat bacterial overgrowth in the small intestine that can exacerbate lactose intolerance indications, is creating a positive outlook for the market. Besides this, the widespread adoption of gut microbiome analysis for identifying specific bacteria that may be causing symptoms and guiding personalized treatment options, is acting as another significant growth-inducing factor. Moreover, numerous key players are making extensive investments in research activities to develop safer and cost-effective targeted therapies with a better understanding of disease pathology. This, in turn, is also propelling the market growth. Additionally, the growing demand for lactase enzyme supplements owing to their several associated benefits, including reduced symptoms, improved nutrient absorption, being well-tolerated with fewer side effects, easy availability, etc., is expected to drive the lactose intolerance market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the lactose intolerance market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for lactose intolerance and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lactose intolerance market in any manner.
Recent Developments:
In February 2024, Novartis announced that Xolair (omalizumab) has been approved by the US FDA to reduce allergic reactions, including anaphylaxis, that can occur after accidental ingestion of one or more foods in pediatric and adult and patients aged 1 year and above with IgE-mediated food allergy. The approval is based on findings from the NIH-sponsored Phase III OUtMATCH research, which demonstrated a considerably higher proportion of food allergy patients as young as one year treated with Xolair could tolerate tiny amounts of peanut, milk, egg, and cashew without an allergic reaction, compared to placebo.
Key Highlights:
About 65 percent of the human population has a diminished capability to digest lactose after infancy.
Lactose intolerance is most common in persons of East Asian heritage, with 70 to 100 percent of those affected in these cultures.
80 percent of all Native Americans and African-Americans are lactose intolerant.
Lactose intolerance appears to be more prevalent in patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D) than in healthy persons.
Lactose intolerance typically manifests in adults between the ages of 20 and 40.
Drugs:
Tilactase is a beta-D-galactosidase isolated from Aspergillus oryzae. The medication is used to treat the symptoms of lactose intolerance in babies and older patients who require parenteral nourishment or a fluid diet. It is produced as a chewable tablet that must be taken before consuming a lactose-containing meal.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the lactose intolerance market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the lactose intolerance market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current lactose intolerance marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the lactose intolerance market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the lactose intolerance market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the lactose intolerance market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of lactose intolerance across the seven major markets?
What is the number of prevalent cases (2018-2034) of lactose intolerance by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of lactose intolerance by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of lactose intolerance by type across the seven major markets?
How many patients are diagnosed (2018-2034) with lactose intolerance across the seven major markets?
What is the size of the lactose intolerance patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of lactose intolerance?
What will be the growth rate of patients across the seven major markets?
Lactose Intolerance: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for lactose intolerance drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lactose intolerance market?
What are the key regulatory events related to the lactose intolerance market?
What is the structure of clinical trial landscape by status related to the lactose intolerance market?
What is the structure of clinical trial landscape by phase related to the lactose intolerance market?
What is the structure of clinical trial landscape by route of administration related to the lactose intolerance market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LACTOSE INTOLERANCE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LACTOSE INTOLERANCE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LACTOSE INTOLERANCE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 LACTOSE INTOLERANCE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LACTOSE INTOLERANCE - UNMET NEEDS
10 LACTOSE INTOLERANCE - KEY ENDPOINTS OF TREATMENT
11 LACTOSE INTOLERANCE - MARKETED PRODUCTS
11.1 List of Lactose Intolerance Marketed Drugs Across the Top 7 Markets
11.1.1 Tilactase - Pro Farma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LACTOSE INTOLERANCE - PIPELINE DRUGS
12.1 List of Lactose Intolerance Pipeline Drugs Across the Top 7 Markets
12.1.1 1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. LACTOSE INTOLERANCE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LACTOSE INTOLERANCE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LACTOSE INTOLERANCE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Lactose Intolerance - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Lactose Intolerance - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Lactose Intolerance - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Lactose Intolerance - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Lactose Intolerance - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Lactose Intolerance - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Lactose Intolerance - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Lactose Intolerance - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Lactose Intolerance - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Lactose Intolerance - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Lactose Intolerance - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Lactose Intolerance - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Lactose Intolerance - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Lactose Intolerance - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Lactose Intolerance - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Lactose Intolerance - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Lactose Intolerance - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Lactose Intolerance - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Lactose Intolerance - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Lactose Intolerance - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Lactose Intolerance - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Lactose Intolerance - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Lactose Intolerance - Access and Reimbursement Overview
16 LACTOSE INTOLERANCE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LACTOSE INTOLERANCE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LACTOSE INTOLERANCE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LACTOSE INTOLERANCE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LACTOSE INTOLERANCE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LACTOSE INTOLERANCE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 LACTOSE INTOLERANCE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LACTOSE INTOLERANCE - UNMET NEEDS
10 LACTOSE INTOLERANCE - KEY ENDPOINTS OF TREATMENT
11 LACTOSE INTOLERANCE - MARKETED PRODUCTS
11.1 List of Lactose Intolerance Marketed Drugs Across the Top 7 Markets
11.1.1 Tilactase - Pro Farma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LACTOSE INTOLERANCE - PIPELINE DRUGS
12.1 List of Lactose Intolerance Pipeline Drugs Across the Top 7 Markets
12.1.1 1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. LACTOSE INTOLERANCE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LACTOSE INTOLERANCE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LACTOSE INTOLERANCE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Lactose Intolerance - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Lactose Intolerance - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Lactose Intolerance - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Lactose Intolerance - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Lactose Intolerance - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Lactose Intolerance - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Lactose Intolerance - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Lactose Intolerance - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Lactose Intolerance - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Lactose Intolerance - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Lactose Intolerance - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Lactose Intolerance - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Lactose Intolerance - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Lactose Intolerance - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Lactose Intolerance - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Lactose Intolerance - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Lactose Intolerance - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Lactose Intolerance - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Lactose Intolerance - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Lactose Intolerance - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Lactose Intolerance - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Lactose Intolerance - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Lactose Intolerance - Access and Reimbursement Overview
16 LACTOSE INTOLERANCE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LACTOSE INTOLERANCE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LACTOSE INTOLERANCE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
